Strives to address unmet need in the treatments of gout and chronic kidney diseases
Location: United States, California, Laguna Hills
Employees: 11-50
Total raised: $75M
Investors 1
| Date | Name | Website |
| - | Heda Ventu... | hedaventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.07.2023 | Series D | $75M | - |
Mentions in press and media 13
| Date | Title | Description |
| 03.09.2024 | The Rise of Private Credit: SeaTown's Bold Move in Asia | In the ever-evolving landscape of finance, private credit is emerging as a formidable player. SeaTown Holdings International, a subsidiary of Temasek, has just closed its second private credit fund, SeaTown Private Credit Fund II (PCF II), ... |
| 29.08.2024 | Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms | Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS net profit reached RMB168.2 million, inc... |
| 06.08.2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 04.12.2023 | Latest Updates of Viva's Portfolio Companies | HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies ... |
| 26.09.2023 | Latest Updates of Viva's Portfolio Companies | HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companie... |
| 12.07.2023 | Arthrosi Therapeutics Raises $75M in Series D Funding | Arthrosi Therapeutics, a San Diego, CA-based a clinical-stage biotechnology company, raised $75M in Series D funding. The round was led by Guangrun Health Industry (Hong Kong) Co. Limited and backed by a consortium of investors, including R... |
| 11.07.2023 | Arthrosi Therapeutics completes $75M Series D round to continue development of their AR882 Inhibitor | - |
| 28.09.2022 | Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi | SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfo... |
| 01.06.2021 | Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results for Gout Patients | |
| 20.04.2021 | Arthrosi Expands Disease Expertise with New Board of Director Appointment | SAN DIEGO, April 20, 2021 /PRNewswire/ -- Arthrosi Therapeutics, Inc. today announced the appointment of James Mackay, PhD, to its board of directors. Dr. Mackay brings more than 30 years of in-depth experience to the team, as they reach Ph... |
Show more